First FDA clearance for TMS in depression; could be effective in coma

The US FDA has granted 510(k) clearance for the first transcranial magnetic stimulation (TMS) device for depression, Neuronetics' Neurostar. The specific indication is for the treatment of adults with major depressive disorder who have not responded to antidepressant drugs.

The US FDA has granted 510(k) clearance for the first transcranial magnetic stimulation (TMS) device for depression, Neuronetics' Neurostar. The specific indication is for the treatment of adults with major depressive disorder who have not responded to antidepressant drugs.

TMS uses an electromagnetic coil to noninvasively stimulate the brain, and was first used in the 1980s. As well as...

More from Archive

More from Medtech Insight